Image Source: Euro News
A comprehensive new study analyzing pricing and affordability of essential medicines across global markets reveals that while richer countries often pay higher nominal prices for medicines, the actual financial burden on their populations is significantly lower compared to low- and middle-income countries. This nuanced finding highlights disparities in medicine affordability and the pressing need for global policies to promote equitable access to vital drugs.
Key Highlights of the Global Medicine Price Study
Researchers evaluated 549 essential medicines listed by the World Health Organization (WHO) across 72 markets, spanning low-, middle-, and high-income countries.
European countries topped the charts in overall spending—recording an average of $192 (around €167) per capita on essential medicines, followed by the Americas.
In contrast, regions like Southeast Asia spent approximately just $7 (around €6) per capita, though affordability—factoring in income levels—is far lower there.
Price comparisons adjusted for purchasing power parity (PPP) revealed an inverse relationship: higher income countries paid more in nominal terms but enjoyed better affordability due to stronger currencies and national subsidies.
For example, while Lebanon’s medicine prices averaged about 18% of German prices after adjustment, the United States paid about three times German prices, reflecting more complex healthcare financing structures.
Affordability Gaps and Economic Burden
Although medicine list prices may appear lower in poorer countries, local populations often face greater financial strain given lower average incomes and higher out-of-pocket payments.
Minimum wage earners in some low-income regions might need to work several days to afford a month’s treatment of common drugs, with chemotherapy medications like paclitaxel costing nearly six weeks’ wages in some countries.
High drug prices in low- and middle-income countries are compounded by lack of subsidies, fragmented procurement policies, and inadequate insurance penetration.
By contrast, many high-income countries subsidize medicine costs extensively, reducing the direct consumer burden despite higher sticker prices.
Coverage, Availability, and Policy Implications
The study found notable disparities in the number of available essential medicines, from 225 (41%) in Kuwait to 438 (80%) in Germany among the surveyed countries.
Medicines addressing major global health burdens such as cardiovascular diseases and mental health disorders generally command higher prices.
Access inequities underscore the need for governments and international organizations to implement clearer regulations, pooled procurement schemes, and pricing transparency.
Achieving Universal Health Coverage (UHC) depends significantly on closing these affordability gaps and ensuring equitable medicine availability globally.
Global Context and Future Directions
As pharmaceutical costs continue to rise worldwide, targeted interventions in pricing policies, subsidies, and supply chain optimization become critical for low-income countries.
The study calls for sustained international cooperation to enable technology and intellectual property transfers, foster generic drug availability, and reduce medicine prices.
New policy frameworks should prioritize affordability, data transparency, and consumer protection while balancing innovation incentives for pharmaceutical companies.
Conclusion
The study clarifies a complex paradox: while wealthy nations pay higher prices for essential medicines, their populations face a proportionally far smaller economic burden compared to those in poorer countries. Policymakers must urgently address structural inequalities through harmonized regulations and equitable pricing models to ensure that life-saving medicines become affordable and accessible to all, regardless of income level or geography.
Sources: Euronews, JAMA Health Forum, Indian Masterminds
Advertisement
Advertisement
